The focus of this project is on differentiation inducers as agents for improving therapeutic selectivity in cancers of lining epithelia. The first hypothesis to be tested is that differentiation-inducers act directly on tumor cells to arrest their growth and divert them toward terminal differentiation. The treatment strategy is to combine two drugs: an agent which induces differentiation of the quiescent (but proliferation-capable) cell subpopulation of the carcinoma and an anti- proliferative drug. This is based on the fact that certain tumor cells are less sensitive to certain cell-cycle arresting agents than normal cells. Three mouse epidermal cell lines which produce well-, moderately- or un-differentiated squamous cell tumors, respectively, in athymic nu/nu mice are compared to the normal parental clone as to the effect and selectively of treatments. In vitro endpoints relative to the first hypothesis are reduction in number and/or area of tumor cell colonies on plastic, and induction of differentiation-stage specific antigens. These include pemphigoid, pemphigus, certain keratins, filaggrin and a cornified envelope precursor protein. Agents found to be active in vitro are tested in vivo. The in vivo endpoints are: 1) ability to reduce growth rate or cause the regression of tumors, and 2) ability to increase the proportion of differentiating tumor cells or to induce a later stage of differentiation in tumors. The latter is detected by indirect immunofluorescence on tissue sections, direct fluorescence of dissociated cells by means of flow cytometry, or Enzyme-linked Immunosorbent assay (ELISA) of tumor tissue extracts coated in microtiter plates. Relative to the second hypothesis, agents found to protect normal epidermal cells in vitro will be tested in vivo for ability to protect lining epithelial cell targets particularly vulnerable to toxicity, including hair follicular and colon epithelium, from anti-proliferative drugs such as 1-beta-D- arabinofuranosylcytosine (Ara-C) and 5-fluorouracil. Test agents include modulators if intracellular Ca++ concentration, retinoids, Ca++- or K+- channel blockers, and modulators of protein kinase C, an enzyme involved in epidermal growth regulation. Information obtained using the mouse epidermal cell model may suggest less toxic approaches to the treatment of human cancers of keratinizing epithelia.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
3P01CA013038-22S3
Application #
6236036
Study Section
Project Start
1994-02-01
Project End
1997-05-15
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
22
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Ojima, Iwao; Borella, Christopher P; Wu, Xinyuan et al. (2005) Design, synthesis and structure-activity relationships of novel taxane-based multidrug resistance reversal agents. J Med Chem 48:2218-28
Berleth, E S; Nadadur, S; Henn, A D et al. (1999) Identification, characterization, and cloning of TIP-B1, a novel protein inhibitor of tumor necrosis factor-induced lysis. Cancer Res 59:5497-506
Huang, B G; Bobek, M (1998) Synthesis and in vitro antitumor activity of some amino-deoxy 7-hexofuranosylpyrrolo[2,3-d]pyrimidines. Carbohydr Res 308:319-28
Ojima, I; Bounaud, P Y; Takeuchi, C et al. (1998) New taxanes as highly efficient reversal agents for multidrug resistance in cancer cells. Bioorg Med Chem Lett 8:189-94
Ehrke, M J; Verstovsek, S; Pocchiari, S K et al. (1998) Thymic anti-tumor effectors in mice cured of lymphoma by cyclophosphamide plus TNF-alpha therapy: phenotypic and functional characterization up to 20 months after initial tumor inoculation. Int J Cancer 76:579-86
Yin, M B; Guo, B; Voigt, W et al. (1998) Novel cellular determinants for reversal of multidrug resistance in cells expressing P170-glycoprotein. Biochim Biophys Acta 1401:265-76
Ehrke, M J; Verstovsek, S; Ujhazy, P et al. (1998) Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice. Cancer Immunol Immunother 45:287-98
Fogel-Petrovic, M; Kramer, D L; Vujcic, S et al. (1997) Structural basis for differential induction of spermidine/spermine N1-acetyltransferase activity by novel spermine analogs. Mol Pharmacol 52:69-74
Sharma, A; Glaves, D; Porter, C W et al. (1997) Antitumor efficacy of N1,N11-diethylnorspermine on a human bladder tumor xenograft in nude athymic mice. Clin Cancer Res 3:1239-44
Kramer, D L; Fogel-Petrovic, M; Diegelman, P et al. (1997) Effects of novel spermine analogues on cell cycle progression and apoptosis in MALME-3M human melanoma cells. Cancer Res 57:5521-7

Showing the most recent 10 out of 135 publications